Imad Hajj1, Mahmoud Al-Masri2, Kaldoun Bashaireh3, Mohammed Bani Hani4, Shadi Hamouri4, Joe Khouzami5, Nisrine Sabra5, Chahine Fadel5. 1. Department of Surgery, Saint George Hospital University Medical Center, Ashrafiyeh, Beirut, Lebanon. iphajj@stgeorgehospital.org. 2. Department of Surgery, King Hussein Cancer Center, PO Box 1269, Al-Jubeiha, Amman, 11941, Jordan. malmasri@khcc.jo. 3. Department of Special Surgery, Faculty of Medicine, Jordan University of Science and Technology, Ar-Ramtha, Jordan. 4. Department of General Surgery and Urology, Faculty of Medicine, Jordan University of Science and Technology, King Abdallah University Hospital, Ar-Ramtha, Jordan. 5. Sanofi, Beirut, Lebanon.
Abstract
BACKGROUND: There is a growing body of evidence showing substantial underuse of appropriate venous thromboembolism (VTE) prophylaxis in patients at risk. In the present study, our goal was to assess the current practices in the use rate of VTE prophylaxis among hospitalized patients in Jordan and Lebanon. METHODS: A cross-sectional, multicenter, observational study was conducted on 40 centers across Lebanon and Jordan. We included patients who were admitted to the participating hospitals for the treatment of a serious medical or surgical illness. The patients' records were screened for the fulfillment of inclusion/exclusion criteria during a single assessment visit. The proportion of medical and surgical patients who were at risk of VTE and the thrombo-prophylactic measures employed by physicians for these patients were assessed according to the American College of Chest Physicians (ACCP 2016) guidelines. RESULTS: The present study included 704 patients (400 from Jordan and 304 from Lebanon) with a mean age of 54.9 ± 17.5 years. Almost 59% of the patients received prophylaxis treatment in form of pharmacological anticoagulant prophylaxis and/or mechanical prophylaxis. Low molecular weight heparin was the most commonly used anticoagulant for VTE prophylaxis in 366 out of the total 704 (51.9%) patients in the analysis cohort. Two hundred and sixteen patients (52, 95% confidence interval [47.1-56.9%]) received appropriate prophylactic agents out of 415 patients who were eligible for prophylaxis according to the ACCP 2016 guidelines. On the other hand, 199 (72.1, 95% confidence interval [66.4-77.3%) patients received prophylaxis out of 276 ineligible patients. The rate of compliance to guidelines showed wide variations according to the type of hospital, specialty, and the patients' age. The multivariate logistic regression analysis showed that only age was a significant predictor of appropriate VTE prophylaxis (odds ratio [OR] 1.05, P < 0.001). CONCLUSION: The rates of the appropriate use of VTE prophylaxis are low in Lebanon and Jordan. There is a lack of compliance to guidelines for VTE prophylaxis use for hospitalized patients in both countries.
BACKGROUND: There is a growing body of evidence showing substantial underuse of appropriate venous thromboembolism (VTE) prophylaxis in patients at risk. In the present study, our goal was to assess the current practices in the use rate of VTE prophylaxis among hospitalized patients in Jordan and Lebanon. METHODS: A cross-sectional, multicenter, observational study was conducted on 40 centers across Lebanon and Jordan. We included patients who were admitted to the participating hospitals for the treatment of a serious medical or surgical illness. The patients' records were screened for the fulfillment of inclusion/exclusion criteria during a single assessment visit. The proportion of medical and surgical patients who were at risk of VTE and the thrombo-prophylactic measures employed by physicians for these patients were assessed according to the American College of Chest Physicians (ACCP 2016) guidelines. RESULTS: The present study included 704 patients (400 from Jordan and 304 from Lebanon) with a mean age of 54.9 ± 17.5 years. Almost 59% of the patients received prophylaxis treatment in form of pharmacological anticoagulant prophylaxis and/or mechanical prophylaxis. Low molecular weight heparin was the most commonly used anticoagulant for VTE prophylaxis in 366 out of the total 704 (51.9%) patients in the analysis cohort. Two hundred and sixteen patients (52, 95% confidence interval [47.1-56.9%]) received appropriate prophylactic agents out of 415 patients who were eligible for prophylaxis according to the ACCP 2016 guidelines. On the other hand, 199 (72.1, 95% confidence interval [66.4-77.3%) patients received prophylaxis out of 276 ineligible patients. The rate of compliance to guidelines showed wide variations according to the type of hospital, specialty, and the patients' age. The multivariate logistic regression analysis showed that only age was a significant predictor of appropriate VTE prophylaxis (odds ratio [OR] 1.05, P < 0.001). CONCLUSION: The rates of the appropriate use of VTE prophylaxis are low in Lebanon and Jordan. There is a lack of compliance to guidelines for VTE prophylaxis use for hospitalized patients in both countries.
Authors: Victor F Tapson; Hervé Decousus; Mario Pini; Beng H Chong; James B Froehlich; Manuel Monreal; Alex C Spyropoulos; Geno J Merli; Rainer B Zotz; Jean-François Bergmann; Ricardo Pavanello; Alexander G G Turpie; Mashio Nakamura; Franco Piovella; Ajay K Kakkar; Frederick A Spencer; Gordon Fitzgerald; Frederick A Anderson Journal: Chest Date: 2007-06-15 Impact factor: 9.410
Authors: Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch Journal: Blood Adv Date: 2018-11-27
Authors: Alexander T Cohen; Victor F Tapson; Jean-Francois Bergmann; Samuel Z Goldhaber; Ajay K Kakkar; Bruno Deslandes; Wei Huang; Maksim Zayaruzny; Leigh Emery; Frederick A Anderson Journal: Lancet Date: 2008-02-02 Impact factor: 79.321